Objectives: Candida non-albicans species cause an increasing proportion of invasive candidiasis (IC). Prompt initiation of effective antifungal therapy has been shown to positively impact the outcomes of IC. Caspofungin is often reserved as a second-line agent after suboptimal response to initial therapy. We determined the impact of the timing of caspofungin administration on outcomes of IC.
Introduction
Candida species are opportunistic fungal pathogens that have become a major cause of nosocomial infections in the USA. In the last 20 years, the prevalence of Candida-associated bloodstream infections has increased steadily, accounting for 8%-10% of all nosocomial bloodstream infections, 1 -3 and Candida species have become the third most common cause of nosocomial bloodstream infections in intensive care units (ICUs). 1 Invasive mycoses are associated with excess morbidity and mortality, 1,2 with a crude mortality of 47% among patients with bloodstream infections in ICUs. 1 Traditionally, Candida albicans is the species most commonly isolated, accounting for 50% -70% of episodes of candidaemia. 3 -6 However, recent changes in the distribution of Candida species involved in invasive candidiasis have strong implications for the selection of initial therapy. More specifically, reduced susceptibility to fluconazole is commonly found in Candida glabrata via an energy-dependent efflux mechanism. 7 Despite the practice of using higher doses of fluconazole for invasive C. glabrata infections, two retrospective studies have found eradication rates of only 54 -65% and mortality rates of 23% -40% with fluconazole monotherapy. 5, 8 Among other variables that could impact treatment response, such as early diagnosis, patient-specific risk factors and severity of illness, the prompt initiation of an appropriate antifungal agent is a significant factor that determines the successful outcome of invasive candidiasis. Previous studies have shown that a delay in the initiation of appropriate antifungal therapy is a significant predictor of mortality. 9 -11 Therefore, prompt initiation and appropriate selection of an antifungal agent are imperative in optimizing treatment outcomes of invasive candidiasis. The use of an echinocandin has been advocated by the Infectious Diseases Society of America (IDSA) for the initial management of invasive candidiasis. 12 The goal of our study was to investigate the impact of time to initiation of caspofungin therapy on treatment outcomes for invasive candidiasis.
Patients and methods

Study design and patient population
A retrospective cohort study of adult patients with invasive candidiasis was conducted at three institutions: St Mary's Medical Center, a 550 bed community teaching hospital; Loma Linda University Medical Center, an 822 bed academic teaching hospital; and St Joseph Hospital, a 525 bed community non-teaching hospital. The study protocol was approved by the Institutional Review Board of each respective institution. The timing of receipt of caspofungin was used as a marker for delayed versus early initiation of therapy. Delayed initiation (DI) versus early initiation (EI) of caspofungin were defined as hospitalized adults who received caspofungin therapy .3 days versus ≤3 days from the time the sample for culture was taken, respectively. The microbiology laboratory computer records were used to identify all patients from whom Candida species were isolated as a causative pathogen of invasive infection from January 2004 to December 2007. The pharmacy drug utilization records were used to identify all patients who received caspofungin therapy during the study period. Inclusion criteria were: (i) age ≥18 years; (ii) isolation of Candida species from blood source only (primary bloodstream), mixed blood and other body site(s), peritoneum or other sterile body sites; (iii) initiation of an antifungal agent within 3 days of isolation of Candida species; and (iv) use of caspofungin for ≥3 consecutive days. Additionally, at least one of the following clinical signs of infection had to be present: fever [a temperature of .100.38F (38.08C)]; hypothermia [a temperature of ,96.88F (36.08C)]; hypotension (systolic blood pressure, ,90 mm Hg or a decrease of .30 mm Hg from baseline); or local signs of inflammation and/or radiological findings that suggest invasive candidiasis. Paediatric patients, repeated episodes of invasive candidiasis from a single patient and immunocompromised patients (patients receiving chemotherapy or immunosuppressive therapy) were excluded from the study.
Data collection and study definitions
The medical and laboratory records of eligible patients were retrospectively reviewed for pertinent demographic, laboratory and clinical data. A structured data collection form was used to record the abstracted data, which were later compiled into a single dataset using a relational database management program (Microsoft Access w ). Demographic data included age, gender, place of residence prior to hospitalization (home, or transferred from outside hospital or facility), source of infection, admission to ICU, total length of stay, length of stay after isolation of organism and co-morbid conditions. Co-morbid conditions included diabetes mellitus, coronary artery disease, cerebrovascular disease, pulmonary disease (asthma or chronic obstructive pulmonary disease), hepatic dysfunction, renal insufficiency, history of malignancy and corticosteroid use. An Acute Physiology and Chronic Health Evaluation II (APACHE II) score was calculated for each patient based on the worst values within 24 h of admission, to assess the severity of underlying illness. 13 The specific antifungal agent(s) used for the treatment of infection, time to initiation of therapy in relation to clinical and microbiological evidence of infection, dosage regimen, and duration of therapy were recorded.
Outcome analysis
Eligible patients were evaluated for the following outcome measures: (i) time to achieve clinical stability; (ii) treatment response; (iii) total length of stay; (iv) length of stay after isolation of organism; and (v) allcause and infection-related in-hospital mortality. Time to achieve clinical stability was defined as return of altered mental status and abnormal vital signs to normal baseline values (heart rate ≤100 beats/min, systolic blood pressure ≥90 mm Hg, respiratory rate ≤24/min, oxygen saturation ≥90% and temperature ≤37.28C). Overall response was evaluated at the end of therapy or 14 days after the initiation of caspofungin, whichever came first. A positive response included complete and partial responses. Complete response was defined as resolution of fever, leucocytosis, sterilization of blood (negative blood culture) and local signs of infections; partial response was defined as improvement of these conditions. Non-response included failure, relapse and death. Failure was defined as no improvement or worsening of signs and symptoms of infection; relapse was defined as recurrence of infection with the same organism at any body site within 1 month after discontinuation of therapy.
Statistical analysis
Descriptive analysis was presented as the mean and median with standard deviation and interquartile ranges (IQRs) for continuous data, and frequency and percentages for discrete data. The Shapiro-Wilk's test was performed to test for normality. Continuous data were evaluated between EI and DI groups using Student's t-test or the MannWhitney U-test, where appropriate. Categorical data were evaluated between EI and DI groups using Pearson's x 2 test or Fisher's exact test, where appropriate. Two-tailed statistical significance was defined as a P value of ≤0.05. Variables that had a P value of ,0.10 in the univariate analysis were used to build the multivariate model. Reverse stepwise logistic regression was performed to determine which variables were statistically associated with patients who responded to therapy. Goodness of fit was evaluated using the Hosmer-Lemeshow test. Reverse stepwise logistic regression was performed in order to control for confounders that may have contributed to differences in outcome measures between the two groups. Statistical analyses were carried out with SPSS version 15.0 (Chicago, IL, USA) and GraphPad Prism version 4.0 (San Diego, CA, USA).
Results
Patient characteristics
A total of 282 invasive candidiasis cases were identified from the microbiology and pharmacy drug utilization records. One hundred and thirteen patients did not qualify under the inclusion/exclusion criteria (58 paediatric cases, 15 cases of repeat episodes, 9 cases of readmission within 1 year and 31 cases involving immunocompromised hosts), resulting in 169 evaluable patients. All of the patients received either caspofungin or fluconazole within 3 days of isolation of Candida species. The study patients represented an elderly population (mean+SD age, 62.35+17.58 years), with almost half (78/169, 46%) residing in a skilled nursing facility prior to admission ( Table 1) . Many of the patients had moderately severe underlying illness (mean+SD APACHE II score, 18.29+7.44) and multiple co-morbidities (mean+SD, 3.26+2.09), such has history of liver disease and heart failure.
Microbiological characteristics
The majority of the infections involved a primary blood source (95/169, 56.2%), followed by mixed blood/other body site (24/ 169, 14.2%), abdomen (44/169, 26.0%) and other sterile sites [pleural abscess (n ¼2) and liver abscess (n¼ 4); 3.6%].
The most commonly isolated species was C. glabrata (78/169, 46.2%), followed by C. albicans (36/169, 21.3%), mixed species (36/169, 21.3%), Candida parapsilosis (9/169, 5.3%), Candida tropicalis (6/169, 3.6%), Candida krusei (2/169, 1.2%) and others (2/169, 1.2%).
Impact of prompt initiation of caspofungin on clinical outcomes
The records for 62 and 107 patients who received delayed versus early initiation of caspofungin, respectively, were evaluated for outcomes. Overall, patients who received delayed caspofungin therapy had poorer clinical outcomes compared with those who received early therapy (Table 2) . No difference in all-cause or infection-related mortality and total length of stay was observed between the two groups. Notably, length of stay after isolation of the infecting organism was significantly longer for patients who received delayed caspofungin therapy. Among those who achieved clinical stability (DI 38/62, 61.3%; EI 68/ 107, 63.6%), the time required for vital signs and mental Caspofungin timing and treatment outcomes status to return to baseline was prolonged by 6.5 days for DI patients (Figure 1 In the univariate analysis, advanced age, increasing number of co-morbidities, infections caused by mixed Candida species, use of fluconazole as the initial agent followed by caspofungin therapy and delayed initiation of caspofungin therapy were significantly associated with poor clinical response (Table 3) . Based on our criteria, the following variables were used to build the multivariate model: age; number of co-morbidities; mixed Candida infections; receipt of fluconazole as a first-line agent; and delayed initiation of caspofungin therapy. The model was a good fit based on the Hosmer -Lemeshow test (0.385). Using reverse stepwise logistic regression to control for confounding variables, both advanced age [odds ratio (OR) 1.05; 95% confidence interval (CI) 1.02 -1.07] and delayed initiation of caspofungin therapy (OR 3.90; 95% CI 1.82-8.40) were found to be significant predictors of poor treatment response.
Discussion
The timing of administration of antifungal agents has a significant impact on treatment outcome. More specifically, previous studies have shown that lower mortality was observed in patients with candidaemia who empirically received fluconazole on day 0, followed by days 1, 2 and ≥3 (P ¼ 0.0009). 9 Furthermore, the initiation of an antifungal agent after 12 h from the time of culture has been identified as a marker for increased mortality. 11 This study examined the impact that timely initiation of caspofungin therapy has on treatment outcomes of invasive candidiasis. In this study, the early initiation of caspofungin appears to positively impact outcomes, even after controlling for a number of co-morbidities, presence of diabetes, infection caused by mixed Candida species and receipt of fluconazole as a first-line agent.
Overall, patients who received caspofungin as first-line therapy were 2.4 times more likely to achieve clinical response and 2 times more likely to achieve clinical stability than those who received fluconazole with a subsequent change to caspofungin. We speculate that the fungicidal activity of caspofungin against Candida species may play a role in achieving earlier control of the infection compared with the fungistatic activity of fluconazole. Previous studies have shown that the fungicidal activity of caspofungin may be observed as early as 3 -7 h for C. albicans and C. tropicalis, 14 whereas fluconazole typically maintains fungistatic activity in 24 h time -kill studies. It should be noted that the fungicidal activity of caspofungin is Patients achieving clinical stability (%) P < 0.0001 Figure 1 . Proportion of patients and time required to achieve clinical stability.
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variable, depending on the isolate, testing conditions (RPMI versus antibiotic medium) and incubation time. 14 -18 We observed a poor response rate of 67% in a significant portion of moderately severe patients (65/97, 67.0%) who initially received fluconazole before changing to caspofungin therapy. Moreover, fluconazole was prescribed as a first-line agent in patients with previously identified risk factors for C. glabrata infection, 6, 7, 19 such as the elderly (34/70, 48.6%) and those with diabetes (34/57, 59.6%), with an observed clinical response of only 47% and 56%, respectively. This finding supports the IDSA recommendation to consider an echinocandin for patients who are more severely ill, with previous history of fluconazole exposure and with increased risk for C. glabrata infection. 12 Our study has several limitations. First, the retrospective design of the study limits the full assessment of variables that can potentially impact treatment outcome. However, the described relationship between timely administration of effective therapy and treatment response in our study is consistent with previously published data. Second, we arbitrarily chose 3 days as the distinguishing marker for early versus late initiation of caspofungin. In our institutions, we use a conventional diagnostic approach that provides Candida species identification anywhere between 36 and 92 h for C. albicans, and up to 124 h for nonalbicans species. 20 Therefore, a classification of early versus delayed initiation using day 3 as the threshold was chosen to reflect the turnaround time for species identification in our practice. This study limitation underscores the importance of appropriate diagnostic testing. A rapid testing technique such as peptide nucleic acid (PNA) fluorescence in situ hybridization, which uses PNA that hybridizes to target DNA or RNA sequences, offers rapid identification (2.5 h turnaround time) of the Caspofungin timing and treatment outcomes JAC respective species involved in invasive candidiasis with .99% sensitivity and specificity. 20 We also recognize that there have been improvements in care that may affect clinical outcome, regardless of antifungal therapy. Moreover, we noticed an increasing utilization of caspofungin, particularly in the latter 2 years. Lastly, data on the susceptibility of the infecting Candida species to caspofungin were not available in most patients, since antifungal susceptibility testing is not routinely performed in the microbiology laboratory at each respective study site. Therefore, we could not assess the impact of the antifungal susceptibility on treatment outcomes.
With the changing epidemiology of invasive candidiasis, the prompt administration of an effective antifungal agent for empirical treatment can have a critical impact on outcomes. In this study, we report the positive impact of early initiation of caspofungin in patients with invasive candidiasis. Prompt initiation of caspofungin for empirical treatment appears to positively impact the outcome of select patient groups with suspected invasive candidiasis-those with advanced age, moderate to severe underlying illness, presence of a significant number of co-morbidities, presence of diabetes and infection caused by mixed Candida species.
